The success of pharmacogenetics in other inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), where genetic factors like TPMT (thiopurine methyltransferase) have already been integrated into clinical practice [11,12], highlights the potential benefits of applying similar personalized approaches in FMF. The gene discussed is TPMT; the disease is rheumatoid arthritis.